Literature DB >> 17408384

4-Phenylbutyrate restores the functionality of a misfolded mutant low-density lipoprotein receptor.

Kristian Tveten1, Øystein L Holla, Trine Ranheim, Knut E Berge, Trond P Leren, Mari A Kulseth.   

Abstract

Familial hypercholesterolemia is an autosomal dominant disease caused by mutations in the gene encoding the low-density lipoprotein receptor. To date, more than 900 different mutations have been described. Transport-defective mutations (class 2) causing partial or complete retention of the receptor in the endoplasmic reticulum are the predominant class of mutations. In a cell culture system (Chinese hamster ovary cells), we show that chemical chaperones are able to mediate rescue of a transport-defective mutant (G544V), and that the ability to obtain rescue is mutation dependent. In particular, the low molecular mass fatty acid derivative 4-phenylbutyrate mediated a marked increase in the transport of G544V-mutant low-density lipoprotein receptor to the plasma membrane. Thirty per cent of the mutant receptor was able to escape from the endoplasmic reticulum and reach the cell surface. The rescued receptor had reduced stability, but was found to be as efficient as the wild-type low-density lipoprotein receptor in binding and internalizing low-density lipoprotein. In addition to 4-phenylbutyrate, we also studied 3-phenylpropionate and 5-phenylvalerate, and compared their effect on rescue of the G544V-mutant low-density lipoprotein receptor with their ability to increase overall gene expression caused by their histone deacetylase inhibitor activity. No correlation was found. Our results indicate that the effect of these agents was not solely mediated by their ability to induce gene expression of proteins involved in intracellular transport, but rather could be due to a direct chemical chaperone activity. These data suggest that rescue of mutant low-density lipoprotein receptor is possible and that it might be feasible to develop pharmacologic chaperones to treat familial hypercholesterolemia patients with class 2 mutations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17408384     DOI: 10.1111/j.1742-4658.2007.05735.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  21 in total

1.  Unfolding the Therapeutic Potential of Chemical Chaperones for Age-related Macular Degeneration.

Authors:  Theodor Sauer; Mrinali Patel; Chi-Chao Chan; Jingsheng Tuo
Journal:  Expert Rev Ophthalmol       Date:  2008-02

Review 2.  Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators.

Authors:  Ania C Muntau; João Leandro; Michael Staudigl; Felix Mayer; Søren W Gersting
Journal:  J Inherit Metab Dis       Date:  2014-04-01       Impact factor: 4.982

3.  Evidence that proteosome inhibitors and chemical chaperones can rescue the activity of retinol dehydrogenase 12 mutant T49M.

Authors:  Seung-Ah Lee; Olga V Belyaeva; Natalia Y Kedishvili
Journal:  Chem Biol Interact       Date:  2011-01-11       Impact factor: 5.192

4.  Effects of cellular, chemical, and pharmacological chaperones on the rescue of a trafficking-defective mutant of the ATP-binding cassette transporter proteins ABCB1/ABCB4.

Authors:  Julien Gautherot; Anne-Marie Durand-Schneider; Danièle Delautier; Jean-Louis Delaunay; Alegna Rada; Julie Gabillet; Chantal Housset; Michèle Maurice; Tounsia Aït-Slimane
Journal:  J Biol Chem       Date:  2011-12-19       Impact factor: 5.157

5.  SEAP activity serves for demonstrating ER stress induction by glucolipotoxicity as well as testing ER stress inhibitory potential of therapeutic agents.

Authors:  Raji Lenin; Viswanathan Mohan; Muthuswamy Balasubramanyam
Journal:  Mol Cell Biochem       Date:  2015-03-17       Impact factor: 3.396

Review 6.  Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk.

Authors:  Sebastiano Calandra; Patrizia Tarugi; Helen E Speedy; Andrew F Dean; Stefano Bertolini; Carol C Shoulders
Journal:  J Lipid Res       Date:  2011-08-23       Impact factor: 5.922

7.  Deletions and missense mutations of EPM2A exacerbate unfolded protein response and apoptosis of neuronal cells induced by endoplasm reticulum stress.

Authors:  Yan Liu; Yin Wang; Cindy Wu; Yang Liu; Pan Zheng
Journal:  Hum Mol Genet       Date:  2009-04-29       Impact factor: 6.150

8.  PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment.

Authors:  Kristian Tveten; Thea Bismo Str M; Knut Erik Berge; Trond P Leren
Journal:  J Lipid Res       Date:  2013-03-18       Impact factor: 5.922

9.  Functional rescue of mutant ABCA1 proteins by sodium 4-phenylbutyrate.

Authors:  Brie Sorrenson; Rachel J Suetani; Michael J A Williams; Vivienne M Bickley; Peter M George; Gregory T Jones; Sally P A McCormick
Journal:  J Lipid Res       Date:  2012-10-20       Impact factor: 5.922

10.  Expression and in vivo rescue of human ABCC6 disease-causing mutants in mouse liver.

Authors:  Olivier Le Saux; Krisztina Fülöp; Yukiko Yamaguchi; Attila Iliás; Zalán Szabó; Christopher N Brampton; Viola Pomozi; Krisztina Huszár; Tamás Arányi; András Váradi
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.